Zentalis presents preclinical azenosertib data in TNBC; real-world ovarian cancer outcomes shown

Zentalis Pharmaceuticals, Inc.

Azenosertib + enfortumab vedotin induced 87.5% complete responses in ADC-resistant TNBC PDX model; 5 of 8 mice had no progression after treatment stop.
Median PFS not reached for azenosertib+EV vs. 22 days for EV alone (HR=0.14, p<0.0001) in TOP1i-ADC-resistant model.
Real-world data: Cyclin E1-positive ovarian cancer patients had shorter time to next treatment (13.2–14.9 months) vs. Cyclin E1-negative (19.5 months), p=0.002.
Azenosertib monotherapy showed 42–99% tumor growth inhibition across 12 TNBC xenograft models.
Data presented at AACR 2026; company plans to explore azenosertib combinations post-ADC in TNBC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.